Marietta Investment Partners LLC Sells 52,728 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marietta Investment Partners LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 76.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 16,401 shares of the biopharmaceutical company’s stock after selling 52,728 shares during the period. Marietta Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $784,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in HALO. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares during the period. Institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on HALO shares. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average price target of $62.78.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 1.3 %

Shares of NASDAQ:HALO opened at $65.16 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The stock has a market cap of $8.02 billion, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The business’s 50 day moving average is $58.20 and its 200 day moving average is $54.76. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.